title: Secretory immunoglobulin A (IgA) responses in IgA nephropathy patients after mucosal immunization, as part of a polymeric IgA response.
abstract: Secretory immunoglobulin A (SIgA), although generated at mucosal surfaces, is also found in low concentrations in the circulation. Recently, SIgA was demonstrated in mesangial deposits of patients with immunoglobulin A nephropathy (IgAN), suggesting a role in the pathogenesis. This finding is in line with the belief that high molecular weight (HMW) immunoglobulin A (IgA) is deposited in the kidney. However, there is little information on the size distribution of antigen-specific IgA in circulation upon mucosal challenge. In this study we measured antigen-specific IgA, including SIgA, in serum following challenge of IgAN patients and controls via intranasal vaccination with a neoantigen, cholera toxin subunit B (CTB). We size-fractionated serum and nasal washes to study the size distribution of total IgA, SIgA and CTB-specific IgA. Finally, we compared the size distribution of antigen-specific IgA after mucosal immunization with the distribution upon systemic immunization. A significant induction of antigen-specific SIgA was detectable in serum of both patients with IgAN and controls after mucosal immunization with CTB. Independent of the route of immunization, in both groups the antigen-specific IgA response was predominantly in the polymeric IgA fractions. This is in contrast to total IgA levels in serum that are predominantly monomeric. We conclude that mucosal challenge results in antigen-specific SIgA in the circulation, and that the antigen-specific IgA response in both IgAN patients and in controls is of predominantly HMW in nature. No differences between IgAN patients and controls were detected, suggesting that the size distribution of antigen-specific IgA in the circulation is not disturbed specifically in IgAN patients.
authors.affiliation: Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: J W
authors.initials: JW
authors.lastname: Eijgenraam
authors.forename: B D
authors.initials: BD
authors.lastname: Oortwijn
authors.forename: S W A
authors.initials: SW
authors.lastname: Kamerling
authors.forename: J W
authors.initials: JW
authors.lastname: de Fijter
authors.forename: A W L
authors.initials: AW
authors.lastname: van den Wall Bake
authors.forename: M R
authors.initials: MR
authors.lastname: Daha
authors.forename: C
authors.initials: C
authors.lastname: van Kooten
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology; D000939:Epitopes; D005260:Female; D005922:Glomerulonephritis, IGA / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization / Q000379:methods; D007070:Immunoglobulin A / Q000096:biosynthesis* / Q000097:blood; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis* / Q000097:blood; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000276:immunology
chemical_list: D000939:Epitopes; D007070:Immunoglobulin A; D007071:Immunoglobulin A, Secretory; C034639:polymeric IgA; D002772:Cholera Toxin